MetLife, Inc.'s Board of Directors has reported a substantial ownership stake in the company's common stock, totaling 100,527,578 shares, which represents 16% of the outstanding shares. This update, filed on November 5, 2026, is significant as it underscores the Board's control over corporate governance and strategic decisions within the company.

The filing indicates that the shares are held under the MetLife Policyholder Trust, which was established as part of a reorganization plan dating back to 1999. The Trust is designed to benefit eligible policyholders, allowing them to have a stake in the company's performance. The Board of Directors holds shared voting power over these shares, which gives them considerable influence in matters brought before MetLife's stockholders.

Background

MetLife, Inc. is a leading provider in the life insurance industry, classified under the Standard Industrial Classification (SIC) code 6311. The company has been actively involved in various recent filings, including several amendments to its Schedule 13D/A, which detail changes in ownership and other significant corporate actions.

In the most recent filing, the Board of Directors disclosed that the number of shares held by the Trust has decreased from 102,098,469 to 100,527,578 due to various transactions, including withdrawals and escheatment of unclaimed shares. The filing also specifies that the Board will direct the voting of these shares on certain matters submitted to a vote of stockholders.

What the Filing Says

"The Board of Directors is reporting beneficial ownership of 100,527,578 shares of Common Stock held by the MetLife Policyholder Trust... The Trust Interests represent undivided fractional interests in the Shares and other assets of the Trust beneficially owned by a Trust Beneficiary through the Custodian."

This statement emphasizes the Board's role in managing the voting rights associated with the shares held in the Trust, which can significantly impact shareholder decisions.

Impact

The filing may affect various stakeholders, including policyholders, shareholders, and competitors within the life insurance industry. As the Board holds a significant portion of shares, their decisions will likely influence MetLife's strategic direction, potentially affecting market competition and investor confidence.

What's Next

The filing does not specify what happens next, leaving stakeholders to speculate on future corporate governance decisions and their implications for MetLife and the broader life insurance industry.